PPT-Tumor -genesis Tumor mutations

Antigen presentation Immune recognition Immune silencing Stage Model for immuno oncology Genomics to diagnose stages Tumor genesis Tumor mutations Antigen presentation Immune recognition. 7th EDITION ANATOMIC STAGE/PROGNOSTIC GROUPSOccult Carcinoma TX N0 Stage 0 Tis N0 NotesThe uncommon supercial spreading tumor of any size with its invasive component limited to the bronchial wall, w DNA pol error rate . ~. 10. -9. per base . copied. How many errors in a . “typical” . somatic cell?. Most errors don’t have detectable effects. But some errors do: . . oncogenes. N. . – dominant. Colin Reisterer and Nick Swenson. S. . Maheswaran. et al. . The New England Journal of Medicine. . 2007. http://www.all-cancer-treatments.com/types-of-lung-cancer.html. Clinical background: Non-small cell lung cancer (NSCLC). Andrew Gentles. CCSB NGS workshop. September 2012. You’ve slogged through QC, trimming, alignment, realignment, variant calling. What next ?. Mutational processes molding the genomes of 21 breast cancers/The life history of 21 breast cancers. Ben Ho Park MD PhD. Johns Hopkins University. Financial Disclosures. I have financial relationships with commercial entities that are relevant to the content of this presentation.. Royalties from Horizon Discovery, LTD. Detection. Luis A. Diaz, M.D.. Johns Hopkins. Mutations are highly specific. Cancer Cell. Normal Cells. Pre-Cancer Cell. Mutations. No Mutations. Access to Somatic Mutations. Tumor Tissue. FFPE. Frozen tissue. npg REVIEW Implications of mitochondrial DNA mutations and mito npg Dr. . Heyam. . Awad. MD, . FRCPath. ILOS. 1.list the main environmental causative agents of cancer.. 2. understand the difference between direct and indirect acting chemical carcinogens.. 3. understand the pathogenesis of cancer development due to several etiologic agents.. Laboratory of Personalized Genomic Medicine . Peter L. Nagy M.D., Ph.D. Assistant Professor. Associate Director, Laboratory of Personalized Genomic Medicine. Department of Pathology and Cell Biology. UW TRT . P01 . Overview. The First TRT PO1 Awarded. Jamey Weichert, PhD, Prof of Radiology, Medical Physics and Pharmaceutics. To develop a broad mechanistic understanding of the immunomodulatory capacity of TRT and to evaluate TRT as . after human tumor initiation? (and why this might be important!) Darryl Shibata Department of Pathology University of Southern California Keck School of Medicine Los Angeles, CA dshibata@usc.edu ~10 . Introduction. Tumor. . can be benign, pre-malignant, or malignant, whereas . cancer. is by definition malignant.. Cancer. . is a group of diseases characterized by . unregulated cell growth . and the . glioblastoma. genes and core pathways. By: Katie . Adolphsen. , Robin Aldrich, Brandon . Hu. , . Nate . Havko. The Cancer Genome Atlas: TCGA. Collaborative effort . $100 million pilot project. Funded by National Cancer Institute and the National Human Genome Research Institute of the National Institutes of Health.